Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16400715 | 0.91 | ALOX15 (0.47) | PARP1SMN1; SMN2CHRNA7HTR3AALDH1A1 | |
| SCHEMBL5745932 | 0.83 | PARP1 (0.46) | PARP1SMN1; SMN2CHRNA7HTR3AALDH1A1 | |
| SCHEMBL30855106 | 0.83 | PARP1 (0.41) | PARP1SMN1; SMN2CHRNA7HTR3AALDH1A1 | |
| SCHEMBL29334524 | 0.83 | PARP1 (0.41) | PARP1SMN1; SMN2CHRNA7HTR3AALDH1A1 | |
| SCHEMBL29115999 | 0.82 | NR1H2 (0.50) | — | |
| SCHEMBL642698 | 0.82 | NR1H2 (0.50) | — | |
| SCHEMBL16401335 | 0.82 | RIPK1 (0.44) | CHRNA7GAA | |
| SCHEMBL7826263 | 0.82 | GAA (0.51) | PARP1SMN1; SMN2CHRNA7HTR3AALDH1A1 | |
| SCHEMBL20449099 | 0.80 | PARP1 (0.53) | PARP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3155289 | 0.80 | PARP1 (0.53) | PARP1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | PARP1 2784/4885SMN1; SMN2 2634/4885CHRNA7 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.